Edition:
United States

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

15.80USD
4:00pm EDT
Change (% chg)

$0.82 (+5.47%)
Prev Close
$14.98
Open
$14.99
Day's High
$15.88
Day's Low
$14.78
Volume
45,862
Avg. Vol
42,828
52-wk High
$19.50
52-wk Low
$12.10

Latest Key Developments (Source: Significant Developments)

Adamas presents positive phase 1A data
8:30am EDT 

May 22 (Reuters) - Adamas Pharmaceuticals Inc ::Adamas presents positive phase 1A data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.Adamas Pharmaceuticals - phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of vimpat.Says multi-dose phase 1b steady state study ongoing, with topline data expected in Q3 2017.Adamas Pharmaceuticals - data from study showed all four formulations of ADS-4101 to be safe and well tolerated when compared to vimpat-treated group.  Full Article

Adamas Pharmaceuticals enters into sales agreement with Cowen
Thursday, 11 May 2017 09:10am EDT 

May 11 (Reuters) - Adamas Pharmaceuticals Inc :Entered into sales agreement with Cowen and co, relating to potential common stock offering of up to $50 million of its shares.  Full Article

Adamas reports Q1 loss per share $0.72
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Adamas Pharmaceuticals Inc :Adamas reports recent achievements and first quarter 2017 financial results.Q1 loss per share $0.72.Q1 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.  Full Article

Adamas reports Q4 loss per share $0.68
Tuesday, 28 Feb 2017 04:05pm EST 

Adamas Pharmaceuticals Inc : Adamas reports recent achievements and financial results for the fourth quarter and full-year 2016 . Q4 loss per share $0.68 . Q4 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S .Adamas pharmaceuticals inc - qtrly loss per share $0.68.  Full Article

Adamas to present new ADS-5102 data from phase 2 trial
Friday, 17 Feb 2017 08:00am EST 

Adamas Pharmaceuticals Inc : Adamas to present new ADS-5102 data from phase 2 trial in walking impairment associated with multiple sclerosis at actrims forum 2017 . Adamas Pharmaceuticals- in study, patients on ads-5102 showed approximate 17 percent placebo-adjusted improvement in walking speed in timed 25 foot walk test . Adamas Pharmaceuticals Inc - in study, patients on ADS-5102 showed approximate three second placebo-adjusted improvement in timed up and go (TUG) test . Adamas Pharmaceuticals Inc - ADS-5102 was generally well tolerated . Adamas Pharmaceuticals Inc - five ADS-5102 patients and no placebo patients discontinued treatment due to AES .Adamas Pharmaceuticals Inc - most frequent adverse events (AES) reported in ads-5102 treatment group were dry mouth, constipation and insomnia.  Full Article

Adamas announces FDA acceptance of ADS-5102 new drug application
Friday, 6 Jan 2017 09:00am EST 

Adamas Pharmaceuticals Inc : Adamas announces FDA acceptance of ADS-5102 new drug application for the treatment of levodopa-induced dyskinesia in patients with parkinson's disease .Adamas Pharmaceuticals Inc - PDUFA action date set for August 24, 2017.  Full Article

Adamas Pharmaceuticals completes phase 1 clinical trial of ADS-4101 for treatment of partial onset seizures in patients with epilepsy
Tuesday, 3 Jan 2017 04:53pm EST 

Adamas Pharmaceuticals Inc : Adamas Pharmaceuticals completes phase 1 clinical trial of ads-4101 for treatment of partial onset seizures in patients with epilepsy .Adamas Pharmaceuticals Inc - "we are encouraged by results of this phase 1 clinical trial in ADS-4101 and look forward to advancing program in 2017".  Full Article

Adamas Pharmaceuticals files for mixed shelf of upto $200 mln
Thursday, 3 Nov 2016 04:45pm EDT 

Adamas Pharmaceuticals Inc - : Files for mixed shelf of upto $200 million - SEC filing .In addition, selling stockholders offer and sellup to 1.6 million shares of common stock.  Full Article

Adamas reports third quarter 2016 financial results
Thursday, 3 Nov 2016 04:05pm EDT 

Adamas Pharmaceuticals Inc : Adamas reports third quarter 2016 financial results . Q3 loss per share $0.66 .Q3 earnings per share view $-0.82 -- Thomson Reuters I/B/E/S.  Full Article

Adamas Pharmaceuticals' ease lid 2 trial is ongoing, and patients are being followed for up to two years
Thursday, 27 Oct 2016 08:05am EDT 

Adamas Pharmaceuticals Inc : Adamas submits new drug application to u.s. Fda for ads-5102 for the treatment of levodopa-induced dyskinesia in patients with parkinson’s disease .Adamas pharmaceuticals inc - ease lid 2 trial is ongoing, and patients are being followed for up to two years.  Full Article

More From Around the Web

BRIEF-Adamas presents positive phase 1A data

* Adamas presents positive phase 1A data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy